Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Allergan presents new FPRL1 receptor ligands

Oct. 8, 2012

No Comments

Intellect Neurosciences and iNovacia enter research service agreement

Oct. 8, 2012

No Comments

FDA approves Cystaran for corneal cystine crystals

Oct. 5, 2012

No Comments

EYEGUARD-C gevokizumab study enters patient enrollment stage

Oct. 5, 2012

No Comments

Omeros completes enrollment in second phase III OMS-302 trial

Oct. 4, 2012

No Comments

FDA panel recommends approval of Argus II Retinal Prosthesis System

Oct. 3, 2012

No Comments

GlaxoSmithKline patents new RIP-2 inhibitors

Oct. 2, 2012

No Comments

Amakem begins phase IIa AMA-0076 trial

Oct. 1, 2012

No Comments

Regeneron's Eylea receives second U.S. approval

Sep. 27, 2012

No Comments

Ohr Pharmaceutical commences phase II trial of squalamine eye drops in wet AMD

Sep. 27, 2012

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

Allergan presents new FPRL1 receptor ligands

Intellect Neurosciences and iNovacia enter research service agreement

FDA approves Cystaran for corneal cystine crystals

EYEGUARD-C gevokizumab study enters patient enrollment stage

Omeros completes enrollment in second phase III OMS-302 trial

FDA panel recommends approval of Argus II Retinal Prosthesis System

GlaxoSmithKline patents new RIP-2 inhibitors

Amakem begins phase IIa AMA-0076 trial

Regeneron's Eylea receives second U.S. approval

Ohr Pharmaceutical commences phase II trial of squalamine eye drops in wet AMD

Today's news in brief

Today's news in brief

Enhanced Cognition: Lewy body dementia phase II pumps stock

Second insulin receptor offers new therapeutic avenues

Experimental mRNA gene therapy suppresses preeclampsia in mice

Ocular RSS

Ocular
RSS